FRIDAY, OCTOBER 18th
1545–1715

**MP04: Prostate Cancer**

**MP-04.01**
Pro-drug Activating Enzyme Gene Over-Expressing Human Adipose Stem Cells Can Inhibit Tumor Growth in Castration Resistant Prostate Cancer with Less Toxicity
Yun Seob Song, South Korea

**MP-04.02**
Randomized Control Study of Prospective Questionnaire Analysis About the Efficacy of a Physical Rehabilitation Exercise Test on Health-Related Quality of Life Using the Smart-After-Care Application in Advanced or Metastatic Prostate Cancer Patients
Sung Han Kim, South Korea

**MP-04.03**
Impact of Gonadotropin-Releasing Hormone Agonist on Cardiovascular Disease and Diabetes Mellitus: A Nationwide Population-Based Cohort Study
Jinseon Cho, South Korea

**MP-04.04**
Tackling Post TRUS Biopsy Sepsis in the Age of Antibiotic Resistance: The Implementation of a Biopsy Protocol Guided by Pre-Biopsy Rectal Swabs
Abdullah Al-Mitwalli, United Kingdom

**MP-04.05**
Is Single or Two Core Prostate Biopsy Sufficient in Metastatic Prostate Cancer: Retrospective Study from Twelve Core Biopsy Cohort
Shrey Jain, India

**MP-04.06**
Clinical Utility of Non-Targeted Prostate Biopsies in Patients in a Multi-Centre MRI-Targeted and Systematic Biopsy Pathway
Martin J. Connor, United Kingdom

**MP-04.07**
Which Men Should Undergo Non-Targeted Systematic Random sampling in an Mpmri-Targeted Pathway: A Multivariable Analysis?
Martin J. Connor, United Kingdom

**MP-04.08**
Transperineal Prostate Mapping Biopsies in Combination with Prostate HistoScanning for Detection of Clinically Significant Prostate Cancer
Alvydas Vezelis, Lithuania

**MP-04.09**
PSA Change Ratio (Post-Biopsy PSA To Pre-Biopsy PSA) as an Independent Predictor of Biochemical Recurrence after Radical Prostatectomy
Bum Soo Kim, South Korea

MP-04.10
Increased Primary Tumour Maximal Standardized Uptake Value (SUVMAX) on 68GA-PSMA PET/CT Correlates with Histologically Aggressive Prostate Cancer
Andrew Morton, Australia

MP-04.11
Urinary ExoRNAs to Diagnose Prostate Cancer
Fubo Wang, China

MP-04.12
Prognostic Role of SII in Castration-Resistant Prostate Cancer Patients with Abiraterone and Enzalutamide
Hirokazu Takeda, Japan

MP-04.13
Use of Transperineal Prostate Biopsy to Assess Accuracy of the Rotterdam Prostate Cancer Risk Calculator and Multiparametric MRI in Predicting Significant Prostate Cancer
Ameet Gupta, United Kingdom

MP-04.14
Diagnostic Accuracy of 68Ga-PSMA PET and mpMRI to Detect Intra-Prostatic Clinically Significant Prostate Cancer Using Whole-Mount Pathology. Impact of the Addition of 68Ga-PSMA PET to mpMRI?
Amer Amin, Australia

MP-04.15
EMAS Gonadal Status Related to the Co-Morbidities and Detection of Significant Prostate Cancer in Japanese Patients Undergoing Prostate Biopsy
Akira Komiya, Japan

MP-04.16
Comparison of MRI-Fusion Biopsy and Standard Transrectal Ultrasound Biopsy: Clinically Significant Prostate Cancer Detection Rate
Teak Jun Shin, South Korea

MP-04.17
High Checkpoint Kinase 2 Expression in Prostate Cancer is a Strong and Independent Prognostic Feature in ERG Negative Prostate Cancer
Till Eichenauer, Germany

MP-04.18
Claudin-1 Upregulation is Associated with Favorable Tumor Features and a Reduced Risk for Biochemical Recurrence in ERG Positive Prostate Cancer
Till Eichenauer, Germany